Literature DB >> 28566619

Berberine Induces Cell Cycle Arrest in Cholangiocarcinoma Cell Lines via Inhibition of NF-κB and STAT3 Pathways.

Nattapong Puthdee1,2, Wunchana Seubwai2,3, Kulthida Vaeteewoottacharn1,2, Thidarut Boonmars2,4, Ubon Cha'on1,2, Chatchai Phoomak1,2, Sopit Wongkham1,2.   

Abstract

Berberine is a natural compound found in several herbs. Anticancer activity of berberine was reported in several cancers, however, little is known regarding the effects of berberine against cholangiocarcinoma (CCA). In this study, the growth inhibitory effects of berberine on CCA cell lines and its molecular mechanisms were explored. Cell growth and cell cycle distribution were examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. The expression levels of cell cycle regulatory proteins were determined by Western blot analysis. Berberine significantly inhibited growth of CCA cell lines in a dose and time dependent fashion. The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-κB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action. These results highlight the potential of berberine to be a multi-target agent for CCA treatment.

Entities:  

Keywords:  berberine; cell cycle arrest; cholangiocarcinoma; nuclear factor-kappaB; signal transducer and activator of transcription 3

Mesh:

Substances:

Year:  2017        PMID: 28566619     DOI: 10.1248/bpb.b16-00428

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

Review 1.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 2.  Recent Advances in Herbal Medicines for Digestive System Malignancies.

Authors:  Jiyao Sheng; Xiaohan Zou; Ziqian Cheng; Yien Xiang; Wei Yang; Yang Lin; Ranji Cui
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

3.  Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.

Authors:  Shuna Sun; Xiaojie Zhang; Mengru Xu; Fang Zhang; Fei Tian; Jianfeng Cui; Yangyang Xia; Chenxi Liang; Shujie Zhou; Haifeng Wei; Hui Zhao; Guojing Wu; Bohan Xu; Xiaochen Liu; Guanqun Yang; Qinzhou Wang; Lei Zhang; Yaoqin Gong; Changshun Shao; Yongxin Zou
Journal:  Cell Death Dis       Date:  2019-03-20       Impact factor: 8.469

4.  hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells.

Authors:  Duo Zhi; Kun Zhou; Dahai Yu; Xiaofan Fan; Juan Zhang; Xiang Li; Mei Dong
Journal:  Oncol Lett       Date:  2019-04-17       Impact factor: 2.967

Review 5.  The role of tumour microenvironment: a new vision for cholangiocarcinoma.

Authors:  Ziyan Chen; Pengyi Guo; Xiaozai Xie; Haitao Yu; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

6.  An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology.

Authors:  Pengfei Guo; Chuipu Cai; Xiaoqin Wu; Xiude Fan; Wei Huang; Jingwei Zhou; Qihui Wu; Yujie Huang; Wei Zhao; Fengxue Zhang; Qi Wang; Yongbin Zhang; Jiansong Fang
Journal:  Front Pharmacol       Date:  2019-08-06       Impact factor: 5.810

Review 7.  Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.

Authors:  Richard Kwamla Amewu; Patrick Opare Sakyi; Dorcas Osei-Safo; Ivan Addae-Mensah
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

Review 8.  Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization.

Authors:  Solomon Habtemariam
Journal:  Molecules       Date:  2020-03-20       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.